Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Metabolism of Strained Rings: Glutathione S-transferase-Catalyzed Formation of a Glutathione-Conjugated Spiro-azetidine without Prior Bioactivation.

Li XQ, Grönberg G, Bangur EH, Hayes MA, Castagnoli N Jr, Weidolf L.

Drug Metab Dispos. 2019 Nov;47(11):1247-1256. doi: 10.1124/dmd.119.088658. Epub 2019 Sep 6.

PMID:
31492694
2.

Hip To Be Square: Oxetanes as Design Elements To Alter Metabolic Pathways.

Toselli F, Fredenwall M, Svensson P, Li XQ, Johansson A, Weidolf L, Hayes MA.

J Med Chem. 2019 Aug 22;62(16):7383-7399. doi: 10.1021/acs.jmedchem.9b00030. Epub 2019 Aug 2.

PMID:
31310524
3.

Corrigendum to 'Drug metabolism and pharmacokinetic strategies for oligonucleotide- and mRNA-based drug development' Drug Discovery Today 23 (2018) 1733-1745.

Andersson S, Antonsson M, Elebring M, Jansson-Löfmark R, Weidolf L.

Drug Discov Today. 2019 Sep;24(9):1953. doi: 10.1016/j.drudis.2018.11.025. Epub 2018 Dec 7. No abstract available.

PMID:
30529076
4.

The metabolic fate of fenclozic acid in chimeric mice with a humanized liver.

Ekdahl A, Weidolf L, Baginski M, Morikawa Y, Thompson RA, Wilson ID.

Arch Toxicol. 2018 Sep;92(9):2819-2828. doi: 10.1007/s00204-018-2274-0. Epub 2018 Aug 9.

5.

Drug metabolism and pharmacokinetic strategies for oligonucleotide- and mRNA-based drug development.

Andersson S, Antonsson M, Elebring M, Jansson-Löfmark R, Weidolf L.

Drug Discov Today. 2018 Oct;23(10):1733-1745. doi: 10.1016/j.drudis.2018.05.030. Epub 2018 May 28. Review. Erratum in: Drug Discov Today. 2019 Sep;24(9):1953.

PMID:
29852223
6.

Oxetane Substrates of Human Microsomal Epoxide Hydrolase.

Toselli F, Fredenwall M, Svensson P, Li XQ, Johansson A, Weidolf L, Hayes MA.

Drug Metab Dispos. 2017 Aug;45(8):966-973. doi: 10.1124/dmd.117.076489. Epub 2017 Jun 9.

PMID:
28600384
7.

Discovery of a Novel Microsomal Epoxide Hydrolase-Catalyzed Hydration of a Spiro Oxetane.

Li XQ, Hayes MA, Grönberg G, Berggren K, Castagnoli N Jr, Weidolf L.

Drug Metab Dispos. 2016 Aug;44(8):1341-8. doi: 10.1124/dmd.116.071142. Epub 2016 Jun 2.

PMID:
27256986
8.

Database Extraction of Metabolite Information of Drug Candidates: Analysis of 27 AstraZeneca Compounds with Human Absorption, Distribution, Metabolism, and Excretion Data.

Iegre J, Hayes MA, Thompson RA, Weidolf L, Isin EM.

Drug Metab Dispos. 2016 May;44(5):732-40. doi: 10.1124/dmd.115.067850. Epub 2016 Feb 11.

PMID:
26868617
9.

Significantly Different Covalent Binding of Oxidative Metabolites, Acyl Glucuronides, and S-Acyl CoA Conjugates Formed from Xenobiotic Carboxylic Acids in Human Liver Microsomes.

Darnell M, Breitholtz K, Isin EM, Jurva U, Weidolf L.

Chem Res Toxicol. 2015 May 18;28(5):886-96. doi: 10.1021/tx500514z. Epub 2015 Apr 8.

PMID:
25803559
10.

Systemic exposure to the metabolites of lesogaberan in humans and animals: a case study of metabolites in safety testing.

Holmberg AA, Ekdahl A, Weidolf L.

Drug Metab Dispos. 2014 Jun;42(6):1016-21. doi: 10.1124/dmd.113.056614. Epub 2014 Mar 21.

PMID:
24658456
11.

Troglitazone metabolism and transporter effects in chimeric mice: a comparison between chimeric humanized and chimeric murinized FRG mice.

Samuelsson K, Pickup K, Sarda S, Foster JR, Randall K, Abrahamsson A, Jacobsen M, Weidolf L, Wilson I.

Xenobiotica. 2014 Jan;44(2):186-95. doi: 10.3109/00498254.2013.879237. Epub 2014 Jan 13.

PMID:
24417752
12.

Metabolism of xenobiotic carboxylic acids: focus on coenzyme A conjugation, reactivity, and interference with lipid metabolism.

Darnell M, Weidolf L.

Chem Res Toxicol. 2013 Aug 19;26(8):1139-55. doi: 10.1021/tx400183y. Epub 2013 Jul 5. Review.

PMID:
23790050
13.

In vitro evaluation of major in vivo drug metabolic pathways using primary human hepatocytes and HepaRG cells in suspension and a dynamic three-dimensional bioreactor system.

Darnell M, Ulvestad M, Ellis E, Weidolf L, Andersson TB.

J Pharmacol Exp Ther. 2012 Oct;343(1):134-44. doi: 10.1124/jpet.112.195834. Epub 2012 Jul 9.

PMID:
22776955
14.

In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs.

Thompson RA, Isin EM, Li Y, Weidolf L, Page K, Wilson I, Swallow S, Middleton B, Stahl S, Foster AJ, Dolgos H, Weaver R, Kenna JG.

Chem Res Toxicol. 2012 Aug 20;25(8):1616-32. doi: 10.1021/tx300091x. Epub 2012 May 31.

PMID:
22646477
15.
16.

Use of radiolabeled compounds in drug metabolism and pharmacokinetic studies.

Isin EM, Elmore CS, Nilsson GN, Thompson RA, Weidolf L.

Chem Res Toxicol. 2012 Mar 19;25(3):532-42. doi: 10.1021/tx2005212. Epub 2012 Feb 28.

PMID:
22372867
17.

Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development.

Thompson RA, Isin EM, Li Y, Weaver R, Weidolf L, Wilson I, Claesson A, Page K, Dolgos H, Kenna JG.

Chem Biol Interact. 2011 Jun 30;192(1-2):65-71. doi: 10.1016/j.cbi.2010.11.002. Epub 2010 Nov 11.

PMID:
21074519
18.

P450-catalyzed vs. electrochemical oxidation of haloperidol studied by ultra-performance liquid chromatography/electrospray ionization mass spectrometry.

Mali'n TJ, Weidolf L, Castagnoli N Jr, Jurva U.

Rapid Commun Mass Spectrom. 2010 May 15;24(9):1231-40. doi: 10.1002/rcm.4505.

PMID:
20391593
19.

In vitro metabolism of haloperidol and sila-haloperidol: new metabolic pathways resulting from carbon/silicon exchange.

Johansson T, Weidolf L, Popp F, Tacke R, Jurva U.

Drug Metab Dispos. 2010 Jan;38(1):73-83. doi: 10.1124/dmd.109.028449.

PMID:
19812350
20.

Novel metabolites of amodiaquine formed by CYP1A1 and CYP1B1: structure elucidation using electrochemistry, mass spectrometry, and NMR.

Johansson T, Jurva U, Grönberg G, Weidolf L, Masimirembwa C.

Drug Metab Dispos. 2009 Mar;37(3):571-9. doi: 10.1124/dmd.108.025171. Epub 2008 Dec 15.

PMID:
19074972
21.

Cytochrome P450-mediated activation of the fragrance compound geraniol forms potent contact allergens.

Hagvall L, Baron JM, Börje A, Weidolf L, Merk H, Karlberg AT.

Toxicol Appl Pharmacol. 2008 Dec 1;233(2):308-13. doi: 10.1016/j.taap.2008.08.014. Epub 2008 Sep 10.

PMID:
18824010
22.

Stereoselective disposition of proton pump inhibitors.

Andersson T, Weidolf L.

Clin Drug Investig. 2008;28(5):263-79. Review.

PMID:
18407713
23.

Electrochemical generation of electrophilic drug metabolites: characterization of amodiaquine quinoneimine and cysteinyl conjugates by MS, IR, and NMR.

Jurva U, Holmén A, Grönberg G, Masimirembwa C, Weidolf L.

Chem Res Toxicol. 2008 Apr;21(4):928-35. doi: 10.1021/tx700400c. Epub 2008 Mar 25.

PMID:
18361508
24.

Mimicry of phase I drug metabolism--novel methods for metabolite characterization and synthesis.

Johansson T, Weidolf L, Jurva U.

Rapid Commun Mass Spectrom. 2007;21(14):2323-31.

PMID:
17575570
25.

State-of-the-art tools for computational site of metabolism predictions: comparative analysis, mechanistical insights, and future applications.

Afzelius L, Arnby CH, Broo A, Carlsson L, Isaksson C, Jurva U, Kjellander B, Kolmodin K, Nilsson K, Raubacher F, Weidolf L.

Drug Metab Rev. 2007;39(1):61-86.

PMID:
17364881
26.

Enantiomer/enantiomer interactions between the S- and R- isomers of omeprazole in human cytochrome P450 enzymes: major role of CYP2C19 and CYP3A4.

Li XQ, Weidolf L, Simonsson R, Andersson TB.

J Pharmacol Exp Ther. 2005 Nov;315(2):777-87. Epub 2005 Aug 10.

PMID:
16093273
28.
29.

Comparison between electrochemistry/mass spectrometry and cytochrome P450 catalyzed oxidation reactions.

Jurva U, Wikström HV, Weidolf L, Bruins AP.

Rapid Commun Mass Spectrom. 2003;17(8):800-10.

PMID:
12672134
30.

Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole.

Andersson T, Hassan-Alin M, Hasselgren G, Röhss K, Weidolf L.

Clin Pharmacokinet. 2001;40(6):411-26. Review.

PMID:
11475467
31.

Study of the electrospray ionization mass spectrometry of the proton pump inhibiting drug Omeprazole.

Weidolf L, Castagnoli N Jr.

Rapid Commun Mass Spectrom. 2001;15(4):283-90.

PMID:
11223960
32.

Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes.

Abelö A, Andersson TB, Antonsson M, Naudot AK, Skånberg I, Weidolf L.

Drug Metab Dispos. 2000 Aug;28(8):966-72.

PMID:
10901708
33.

Stereoselective metabolism by human liver CYP enzymes of a substituted benzimidazole.

Abelö A, Andersson TB, Bredberg U, Skånberg I, Weidolf L.

Drug Metab Dispos. 2000 Jan;28(1):58-64.

PMID:
10611141
34.
35.

High-performance liquid chromatographic assay for human liver microsomal omeprazole metabolism.

Andersson T, Lagerstrøm PO, Miners JO, Veronese ME, Weidolf L, Birkett DJ.

J Chromatogr. 1993 Sep 22;619(2):291-7.

PMID:
8263101
37.

A metabolic route of omeprazole involving conjugation with glutathione identified in the rat.

Weidolf L, Karlsson KE, Nilsson I.

Drug Metab Dispos. 1992 Mar-Apr;20(2):262-7.

PMID:
1352219
38.
39.
40.
41.

Biotransformation of felodipine in liver microsomes from rat, dog, and man.

Bäärnhielm C, Backman A, Hoffmann KJ, Weidolf L.

Drug Metab Dispos. 1986 Sep-Oct;14(5):613-8.

PMID:
2876870
42.
43.

Identification of felodipine metabolites in rat urine.

Hoffmann KJ, Weidolf L.

Biomed Mass Spectrom. 1985 Aug;12(8):414-23.

PMID:
2931132
44.

Absorption, distribution and elimination of felodipine in man.

Edgar B, Hoffmann KJ, Lundborg P, Regårdh CG, Rönn O, Weidolf L.

Drugs. 1985;29 Suppl 2:9-15.

PMID:
3987557
45.

Urinary metabolites of felodipine, a new vasodilator drug, in man, dog, rat and mouse.

Weidolf L, Borg KO, Hoffmann KJ.

Xenobiotica. 1984 Aug;14(8):657-66.

PMID:
6495759
47.

Synthesis and preparative liquid chromatographic purification of reference compounds of three metabolites of the vasodilating drug felodipine.

Weidolf L, Hoffmann KJ, Carlsson S, Borg KO.

Acta Pharm Suec. 1984;21(4):209-22. No abstract available.

PMID:
6516867

Supplemental Content

Loading ...
Support Center